Page last updated: 2024-10-18

ethanolamine and Fatty Liver, Nonalcoholic

ethanolamine has been researched along with Fatty Liver, Nonalcoholic in 1 studies

Research Excerpts

ExcerptRelevanceReference
"Metabolic disorders such as type 2 diabetes, fatty liver disease, hyperlipidemia, and obesity commonly co-occur but clinical treatment options do not effectively target all disorders."2.44Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice. ( Alexopoulos, SJ; Beretta, M; Byrne, FL; Cantley, J; Chen, SY; Garcia, CJ; Hoehn, KL; Larance, M; Olzomer, EM; Philp, A; Salamoun, JM; Santos, WL; Shah, DP; Smith, GC; Turner, N, 2024)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, SY1
Beretta, M1
Olzomer, EM1
Alexopoulos, SJ1
Shah, DP1
Byrne, FL1
Salamoun, JM1
Garcia, CJ1
Smith, GC1
Larance, M1
Philp, A1
Turner, N1
Santos, WL1
Cantley, J1
Hoehn, KL1

Other Studies

1 other study available for ethanolamine and Fatty Liver, Nonalcoholic

ArticleYear
Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
    Biochimica et biophysica acta. Molecular basis of disease, 2024, Volume: 1870, Issue:1

    Topics: Animals; Caloric Restriction; Diabetes Mellitus, Type 2; Ethanolamine; Ethanolamines; Female; Mice;

2024